(Q24246372)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

title

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

J Cody

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

C Daly

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Campbell

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

C Donaldson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

I Khan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

K Rabindranath

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

L Vale

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Macleod

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

20 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

CD003266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Anaemia in diabetes: Is there a rationale to TREAT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Cloning and expression of the human erythropoietin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Implications of recombinant erythropoietin therapy for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

An Ongoing Study of Anemia Correction in Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

A comparison of statistical methods for combining event rates from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Safety and efficacy of erythropoietin in children with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Effect of early correction of anemia on the progression of CKD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

The CREATE trial--building the evidence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Anemia and cardiovascular risk: the lesson of the CREATE Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003266.PUB2

7 January 2021

10.1002/14651858.CD003266.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16034896%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017